February 16, 2026
Medical Disposables and Supplies Limited (MDS)
Unaudited financials for the nine months ended December 31, 2025:
Medical Disposables and Supplies Limited (MDS), for the nine months ended December 31, 2025, reported a 2% increase in Revenue totaling $2.93 billion compared to $2.87 billion in the corresponding period last year. Revenue for the third quarter recorded a 6% decrease to close at $924.67 million compared to $987.28 million for the comparable quarter of 2024.
Cost of Sales amounted to $2.27 billion (2024: $2.21 billion), representing an increase of 3% year over year. Consequently, gross profit decreased by 1% to $653.64 million compared to $662.35 million for the nine months ended December 31, 2024. The company booked gross profit of $200.35 million for the third quarter versus $223.33 million reported for the similar quarter of 2024.
Administrative expenses increased by 3% to close at $412.56 million (2024: $400.31 million), while selling and promotional costs decreased by 6% from $248.02 million in 2024 to $232.50 million in the period under review. As a result, total operating expenses for the nine months ended December 31, 2025, amounted to $668.99 million, a 1% decrease relative to $675.21 million reported in 2024.
Operating loss for the nine months ended December 31, 2025, amounted to $15.35 million, reflecting an increase relative to $12.86 million reported in 2024. Operating loss for the third quarter amounted to $23.30 million (2024: $19.86 million).
Finance income totaled $228,030, a 47% increase from the corresponding period last year (2024: $154,730), while finance costs totaled $104.81 million, a 3% decrease from the corresponding period last year (2024: $107.57 million).
Loss for the year for the nine months amounted to $78.59 million, a 24% decrease from the $103.54 million reported in 2024. For the third quarter, loss for the year was $55.36 million (2024: $55.63 million). Net loss attributable to shareholders for the nine months amounted to $64.25 million (2024: net loss attributable to shareholders of $86.14 million).
Consequently, Loss Per Share for the nine months amounted to $0.24 (2024: LPS: $0.33), while Loss Per Share for the quarter totaled $0.16 (2024: LPS: $0.19). The twelve-month trailing LPS was $0.68, and the number of shares used in these calculations was 263,157,895.
Notably, MDS’s stock price closed the trading period on February 12, 2026, at a price of $1.35.
Balance Sheet Highlights:
The company’s assets totaled $3.03 billion, a 1% increase from $3.00 billion booked in 2024. This increase was attributable to property, plant and equipment, which amounted to $1.00 billion (2024: $736.33 million).
Shareholders’ equity was $894.63 million (2024: $682.98 million), representing a book value per share of $3.40 (2024: $2.60).
Disclaimer:
Analyst Certification – The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation (s) or view (s) expressed by that research analyst in this research report.
Company Disclosure – The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein
